Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development

Fredrik H. Karlsson, Salim Bouchene, Constanze Hilgendorf, Hugues Dolgos and Sheila Annie Peters
Drug Metabolism and Disposition December 2013, 41 (12) 2033-2046; DOI: https://doi.org/10.1124/dmd.113.051664
Fredrik H. Karlsson
Cardiovascular and Gastrointestinal Drug Metabolism and Pharmacokinetics (F.H.K., S.B.), Global Drug Metabolism and Pharmacokinetics (C.H., H.D.), and Respiratory, Inflammation and Autoimmunity, Innovative Medicines Drug Metabolism and Pharmacokinetics (S.A.P.), AstraZeneca R&D, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salim Bouchene
Cardiovascular and Gastrointestinal Drug Metabolism and Pharmacokinetics (F.H.K., S.B.), Global Drug Metabolism and Pharmacokinetics (C.H., H.D.), and Respiratory, Inflammation and Autoimmunity, Innovative Medicines Drug Metabolism and Pharmacokinetics (S.A.P.), AstraZeneca R&D, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Constanze Hilgendorf
Cardiovascular and Gastrointestinal Drug Metabolism and Pharmacokinetics (F.H.K., S.B.), Global Drug Metabolism and Pharmacokinetics (C.H., H.D.), and Respiratory, Inflammation and Autoimmunity, Innovative Medicines Drug Metabolism and Pharmacokinetics (S.A.P.), AstraZeneca R&D, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugues Dolgos
Cardiovascular and Gastrointestinal Drug Metabolism and Pharmacokinetics (F.H.K., S.B.), Global Drug Metabolism and Pharmacokinetics (C.H., H.D.), and Respiratory, Inflammation and Autoimmunity, Innovative Medicines Drug Metabolism and Pharmacokinetics (S.A.P.), AstraZeneca R&D, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheila Annie Peters
Cardiovascular and Gastrointestinal Drug Metabolism and Pharmacokinetics (F.H.K., S.B.), Global Drug Metabolism and Pharmacokinetics (C.H., H.D.), and Respiratory, Inflammation and Autoimmunity, Innovative Medicines Drug Metabolism and Pharmacokinetics (S.A.P.), AstraZeneca R&D, Mölndal, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

A growing awareness of the risks associated with extensive intestinal metabolism has triggered an interest in developing robust methods for its quantitative assessment. This study explored the utility of intestinal S9 fractions, human liver microsomes, and recombinant cytochromes P450 to quantify CYP3A-mediated intestinal extraction in humans for a selection of marketed drugs that are predominantly metabolized by CYP3A4. A simple competing rates model is used to estimate the fraction of drug escaping gut wall metabolism (fg) from in vitro intrinsic clearance in humans. The fg values extrapolated from the three in vitro systems used in this study, together with literature-derived fg from human intestinal microsomes, were validated against fg extracted from human in vivo pharmacokinetic (PK) profiles using a generic whole-body physiologically-based pharmacokinetic (PBPK) model. The utility of the rat as a model for human CYP3A-mediated intestinal metabolism was also evaluated. Human fg from PBPK compares well with that from the grapefruit juice method, justifying its use for the evaluation of human in vitro systems. Predictive performance of all human in vitro systems was comparable [root mean square error (RMSE) = 0.22–0.27; n = 10]. Rat fg derived from in vivo PK profiles using PBPK has the lowest RMSE (0.19; n = 11) for the prediction of human fg for the selected compounds, most of which have a fraction absorbed close to 1. On the basis of these evaluations, the combined use of fg from human in vitro systems and rats is recommended for the estimation of CYP3A4-mediated intestinal metabolism in lead optimization and preclinical development phases.

Footnotes

    • Received February 27, 2013.
    • Accepted August 5, 2013.
  • ↵1 Current affiliation: Chalmers University of Technology, Gothenburg, Sweden.

  • ↵2 Current affiliation: Uppsala University, Uppsala, Sweden.

  • ↵3 Current affiliation: Merck KGaA, Darmstadt, Germany.

  • dx.doi.org/10.1124/dmd.113.051664.

  • ↵Embedded ImageThis article has supplemental material available at dmd.aspetjournals.org.

  • Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 41 (12)
Drug Metabolism and Disposition
Vol. 41, Issue 12
1 Dec 2013
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

Prediction of Human Intestinal First-Pass Metabolism

Fredrik H. Karlsson, Salim Bouchene, Constanze Hilgendorf, Hugues Dolgos and Sheila Annie Peters
Drug Metabolism and Disposition December 1, 2013, 41 (12) 2033-2046; DOI: https://doi.org/10.1124/dmd.113.051664

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleSpecial Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

Prediction of Human Intestinal First-Pass Metabolism

Fredrik H. Karlsson, Salim Bouchene, Constanze Hilgendorf, Hugues Dolgos and Sheila Annie Peters
Drug Metabolism and Disposition December 1, 2013, 41 (12) 2033-2046; DOI: https://doi.org/10.1124/dmd.113.051664
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • In Vitro–In Vivo Correlation of P-gp Efflux Ratio
  • Heterotropic Activation of CYP3A by a Novel mGlu5 PAM
  • IVIVC of Low Clearance
Show more Special Section on Prediction of Human Pharmacokinetic Parameters from In Vitro Systems

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics